WO2007071766A3 - Phenoxy acetic acids as ppar delta activators - Google Patents
Phenoxy acetic acids as ppar delta activators Download PDFInfo
- Publication number
- WO2007071766A3 WO2007071766A3 PCT/EP2006/070096 EP2006070096W WO2007071766A3 WO 2007071766 A3 WO2007071766 A3 WO 2007071766A3 EP 2006070096 W EP2006070096 W EP 2006070096W WO 2007071766 A3 WO2007071766 A3 WO 2007071766A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- acetic acids
- ppar delta
- phenoxy acetic
- activators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/16—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
Abstract
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006327003A AU2006327003B2 (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as PPAR delta activators |
CA2631390A CA2631390C (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as ppar delta activators |
ES06830789T ES2386734T3 (en) | 2005-12-22 | 2006-12-21 | Phenoxyacetic acids as activators of PPAR-DELTA |
EP06830789A EP1979311B1 (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as ppar delta activators |
JP2008546470A JP5054028B2 (en) | 2005-12-22 | 2006-12-21 | New compounds, their manufacture and use |
NZ568488A NZ568488A (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as PPAR delta activators |
EA200870103A EA015717B1 (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as ppar delta activators |
BRPI0620468-6A BRPI0620468A2 (en) | 2005-12-22 | 2006-12-21 | acetic phenoxy acids as activators of delta ppar |
US12/097,564 US7943613B2 (en) | 2005-12-22 | 2006-12-21 | Compounds, their preparation and use |
IL191655A IL191655A (en) | 2005-12-22 | 2008-05-22 | Phenoxy acetic acids or pharmaceutically acceptable salts or hydrates thereof and pharmaceutical compositions comprising the same |
KR1020087016288A KR101265078B1 (en) | 2005-12-22 | 2008-07-04 | Phenoxy acetic acids as ppar delta activators |
US13/079,460 US8362016B2 (en) | 2005-12-22 | 2011-04-04 | Phenyl propionic acids as PPAR delta activators |
US13/708,163 US8551993B2 (en) | 2005-12-22 | 2012-12-07 | Phenoxy acetic acids as PPAR delta activators |
US14/016,442 US9663481B2 (en) | 2005-12-22 | 2013-09-03 | Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists |
US15/490,205 US9855274B2 (en) | 2005-12-22 | 2017-04-18 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US15/817,470 US10471066B2 (en) | 2005-12-22 | 2017-11-20 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US16/679,026 US10947180B2 (en) | 2005-12-22 | 2019-11-08 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
US17/196,873 US11420929B2 (en) | 2005-12-22 | 2021-03-09 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112758 | 2005-12-22 | ||
EP05112758.7 | 2005-12-22 | ||
EP06115631 | 2006-06-19 | ||
EP06115631.1 | 2006-06-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/097,564 A-371-Of-International US7943613B2 (en) | 2005-12-22 | 2006-12-21 | Compounds, their preparation and use |
US13/079,460 Continuation US8362016B2 (en) | 2005-12-22 | 2011-04-04 | Phenyl propionic acids as PPAR delta activators |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007071766A2 WO2007071766A2 (en) | 2007-06-28 |
WO2007071766A3 true WO2007071766A3 (en) | 2007-09-13 |
Family
ID=38055174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/070096 WO2007071766A2 (en) | 2005-12-22 | 2006-12-21 | Phenoxy acetic acids as ppar delta activators |
Country Status (14)
Country | Link |
---|---|
US (8) | US7943613B2 (en) |
EP (2) | EP1979311B1 (en) |
JP (1) | JP5054028B2 (en) |
KR (1) | KR101265078B1 (en) |
CN (1) | CN103224477A (en) |
AU (1) | AU2006327003B2 (en) |
BR (1) | BRPI0620468A2 (en) |
CA (1) | CA2631390C (en) |
EA (3) | EA201101084A1 (en) |
ES (1) | ES2386734T3 (en) |
IL (1) | IL191655A (en) |
NZ (1) | NZ568488A (en) |
TW (1) | TWI389878B (en) |
WO (1) | WO2007071766A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE515494T1 (en) * | 2004-05-05 | 2011-07-15 | High Point Pharmaceuticals Llc | NEW COMPOUNDS, THEIR PRODUCTION AND USE |
EP1763511B1 (en) * | 2004-05-05 | 2010-07-28 | High Point Pharmaceuticals, LLC | Phenoxyacetic acid derivatives as ppar agonists |
CN103224477A (en) * | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | Phenoxy acetic acids as PPAR delta activators |
ITMI20071261A1 (en) * | 2007-06-22 | 2008-12-23 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF CINACALCET |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
JP2013006769A (en) * | 2009-10-08 | 2013-01-10 | Nippon Chemiphar Co Ltd | Activator for peroxisome proliferator activating receptor |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
WO2011157827A1 (en) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (en) | 2011-03-08 | 2015-04-22 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP5929109B2 (en) * | 2011-11-11 | 2016-06-01 | デクセリアルズ株式会社 | Novel ethynylbenzophenone compounds or analogs thereof |
WO2015033418A1 (en) * | 2013-09-05 | 2015-03-12 | 株式会社日立製作所 | Storage system and storage control method |
EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
GB201318886D0 (en) * | 2013-10-25 | 2013-12-11 | Givaudan Sa | Improvements i or relating to organic compounds |
WO2020172421A1 (en) * | 2019-02-20 | 2020-08-27 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of mitochondrial myopathy |
JP2022548725A (en) * | 2019-09-20 | 2022-11-21 | レネオ ファーマシューティカルズ,インク. | Use of PPARdelta agonists in treating kidney disease |
JP2023534835A (en) * | 2020-07-22 | 2023-08-14 | レネオ ファーマシューティカルズ,インク. | Crystalline PPAR delta agonist |
KR20230112685A (en) * | 2020-11-25 | 2023-07-27 | 르네오 파마슈티컬스, 인크. | Methods of making PPAR-delta agonists |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011807A1 (en) * | 2001-07-30 | 2003-02-13 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
WO2004037775A1 (en) * | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds useful in treating ppar mediated diseases |
WO2004037776A2 (en) * | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds and their use as prar-modulators |
WO2005105735A1 (en) * | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Phenoxyacetic acid derivatives as ppar agonists |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2331336A1 (en) | 1975-11-14 | 1977-06-10 | Rolland Sa A | OXY-4,4'BIS ACIDS (2-PHENOXY ALKANOCARBOXYLIC), THEIR DERIVATIVES AND THEIR APPLICATION AS A MEDICINAL PRODUCT |
US4920132A (en) | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US5324743A (en) | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
IL109451A0 (en) | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
IL125071A0 (en) | 1996-01-17 | 1999-01-26 | Novo Nordisk As | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives their preparation and use |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
WO1997027847A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
ATE236137T1 (en) | 1996-02-02 | 2003-04-15 | Merck & Co Inc | HETEROCYCLIC COMPOUNDS AS ANTIDIABETIC AGENTS AND FOR THE TREATMENT OF OBESITY |
WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
ATE262334T1 (en) | 1996-02-02 | 2004-04-15 | Merck & Co Inc | ANTIDIABETIC AGENT |
AU2652397A (en) | 1996-05-13 | 1997-12-05 | Nippon Shinyaku Co. Ltd. | Substituted ethylene compounds and drugs |
US5773469A (en) | 1996-06-18 | 1998-06-30 | Ortho Pharmaceutical Corporation | Diaryl antimicrobial agents |
WO1997048876A1 (en) | 1996-06-21 | 1997-12-24 | Smith International, Inc. | Rolling cone bit having gage and nestled gage cutter elements having enhancements in materials and geometry to optimize borehole corner cutting duty |
CA2264243C (en) | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
AU719663B2 (en) | 1996-12-23 | 2000-05-11 | Merck & Co., Inc. | Antidiabetic agents |
AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
CA2294830A1 (en) | 1997-07-16 | 1999-01-28 | John Bondo Hansen | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
ES2320181T3 (en) | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITIONS THAT HAVE A REDUCING EFFECT OF CHOLESTEROL. |
PL344977A1 (en) | 1997-10-17 | 2001-11-19 | Aventis Pharm Prod Inc | Therapeutic uses of quinoline derivatives |
US6972294B1 (en) | 1999-04-20 | 2005-12-06 | Novo Nordisk, A/S | Compounds, their preparation and use |
CA2367356A1 (en) | 1999-04-20 | 2000-10-26 | Per Sauerberg | New compounds, their preparation and use |
MXPA01012493A (en) | 1999-06-01 | 2003-09-10 | Univ Texas Southwestern Med Ct | Method of treating hair loss using diphenylether derivatives. |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
US6368155B1 (en) | 1999-07-16 | 2002-04-09 | Molex Incorporated | Intelligent sensing connectors |
TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
US6369098B1 (en) | 1999-10-05 | 2002-04-09 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
HUP0203837A2 (en) | 1999-11-10 | 2003-03-28 | Takeda Chemical Industries, Ltd. | Body weight gain inhibitors |
IL148579A0 (en) | 1999-11-11 | 2002-09-12 | Lilly Co Eli | Oncolytic combinations for the treatment of cancer |
KR20020090211A (en) | 2000-01-28 | 2002-11-30 | 노보 노르디스크 에이/에스 | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
US6569901B2 (en) | 2000-01-28 | 2003-05-27 | Novo Nordisk A/S | Alkynyl-substituted propionic acid derivatives, their preparation and use |
AU2831901A (en) | 2000-01-28 | 2001-08-07 | Novo Nordisk A/S | Propionic acid derivatives and their use in the treatment of diabetes and obesity |
US6555577B1 (en) | 2000-01-28 | 2003-04-29 | Novo Nordisk A/S | Compounds, their preparation and use |
EP1259494A4 (en) | 2000-02-18 | 2004-09-15 | Merck & Co Inc | Aryloxyacetic acids for diabetes and lipid disorders |
CA2402315A1 (en) | 2000-03-09 | 2001-09-13 | Michael Jaye | Therapeutic uses of ppar mediators |
US6448293B1 (en) | 2000-03-31 | 2002-09-10 | Pfizer Inc. | Diphenyl ether compounds useful in therapy |
JP2001354671A (en) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR delta |
JP2004501076A (en) | 2000-04-17 | 2004-01-15 | ノボ ノルディスク アクティーゼルスカブ | New compounds, their production and use |
EP1285058A2 (en) | 2000-05-18 | 2003-02-26 | Schering Aktiengesellschaft | Fertilization of aged oocytes |
CN1338310A (en) | 2000-08-10 | 2002-03-06 | 清华大学 | Epitope vaccine of hog cholera virus and its preparing process |
WO2002014291A1 (en) | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
JP2004509084A (en) | 2000-08-23 | 2004-03-25 | イーライ・リリー・アンド・カンパニー | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
US6630504B2 (en) | 2000-08-31 | 2003-10-07 | Pfizer Inc. | Phenoxyphenylheterocyclyl derivatives as SSRIs |
GB0024361D0 (en) | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
JPWO2002046154A1 (en) | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | Activator of peroxisome proliferator-activated receptor δ |
GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
WO2002053547A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
AU2002243778A1 (en) | 2001-02-02 | 2002-09-19 | Smithkline Beecham Corporation | Treatment of ppar mediated diseases |
JP4157381B2 (en) | 2001-03-23 | 2008-10-01 | 日本ケミファ株式会社 | Activator of peroxisome proliferator-responsive receptor |
US7253178B2 (en) | 2001-03-28 | 2007-08-07 | Eisai Co., Ltd. | Carboxylic acids |
JPWO2002080899A1 (en) | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | Gastrointestinal disease treatment |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
US7687664B2 (en) | 2001-06-04 | 2010-03-30 | Eisai R&D Management Co., Ltd. | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it |
NL1018283C2 (en) | 2001-06-13 | 2002-12-19 | Dsm Nv | Process for contacting molten urea with a gas stream. |
FR2826574B1 (en) | 2001-06-29 | 2005-08-26 | Oreal | COMPOSITIONS CONTAINING A HYDROXYDIPHENYL ETHER DERIVATIVE INHIBITING THE DEVELOPMENT OF BODY ODORS |
EP1414785A1 (en) | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
US6869967B2 (en) | 2001-07-30 | 2005-03-22 | Novo Nordisk A/S | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
EP1424330B1 (en) | 2001-08-10 | 2011-09-28 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-responsive receptor delta |
US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
JP4269052B2 (en) | 2001-09-14 | 2009-05-27 | アムジエン・インコーポレーテツド | Linked biaryl compounds |
DE60232739D1 (en) | 2001-10-12 | 2009-08-06 | Nippon Chemiphar Co | ACTIVATOR OF THE PEROXISOMPROLIFERATOR-ACTIVATED RECEPTOR DELTA |
US7220877B2 (en) | 2001-10-17 | 2007-05-22 | Novo Nordisk A/S | Compounds, their preparation and use |
CA2462514A1 (en) | 2001-10-17 | 2003-04-24 | Lone Jeppesen | Dicarboxylic acid derivatives, their preparation and therapeutical use |
DE10151390A1 (en) | 2001-10-18 | 2003-05-08 | Bayer Ag | acetic acid derivatives |
JP2003171275A (en) | 2001-12-11 | 2003-06-17 | Sumitomo Pharmaceut Co Ltd | Ppar delta agonist |
US7153878B2 (en) | 2002-02-25 | 2006-12-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
EP1480957A1 (en) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
DE10222034A1 (en) | 2002-05-17 | 2003-11-27 | Bayer Ag | New 2-benzenesulfonyl-3,4-dihydro-2(1H)-isoquinoline derivatives, are PPAR-delta activators useful e.g. for treating coronary heart disease, dyslipidemia or restenosis |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
GB0214254D0 (en) | 2002-06-20 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
US20040127537A1 (en) | 2002-06-26 | 2004-07-01 | Gokarn Yatin R. | Stable liquid parenteral parecoxib formulation |
DE10229777A1 (en) | 2002-07-03 | 2004-01-29 | Bayer Ag | Indoline-phenylsulfonamide derivatives |
WO2004007439A1 (en) | 2002-07-10 | 2004-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | Biaryl derivatives |
MXPA05002411A (en) | 2002-09-05 | 2005-05-27 | Novo Nordisk As | Novel vinyl carboxylic acid derivatives and their therapeutical use. |
WO2004037778A1 (en) | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes |
US7129268B2 (en) | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
WO2004063165A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | A pyrazole derivative as ppar modulator |
DE10300099A1 (en) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Indole-phenylsulfonamide derivatives |
EP1597248B1 (en) | 2003-02-14 | 2007-12-26 | Eli Lilly And Company | Sulfonamide derivatives as ppar modulators |
US20070105959A1 (en) | 2003-03-11 | 2007-05-10 | Shinya Kusuda | Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient |
AU2004220221A1 (en) | 2003-03-13 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | Imino ether derivative compounds and drugs containing the compounds as the active ingredient |
WO2004092117A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
WO2004093879A1 (en) | 2003-04-17 | 2004-11-04 | Kalypsys, Inc. | (3-{3-‘(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders |
WO2004099170A2 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
CA2547212A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
WO2005097096A1 (en) | 2004-03-31 | 2005-10-20 | Pharmacia & Upjohn Company Llc | A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders |
BRPI0509540A (en) | 2004-04-01 | 2007-09-18 | Aventis Pharma Inc | use of peroxisome proliferator-activated delta receptor agonists for the treatment of ms and other demyelinating diseases |
WO2005097762A2 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as ppar delta modulators |
AU2005230838A1 (en) | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
US20070185168A1 (en) | 2004-04-07 | 2007-08-09 | Takai Haruki S | Piperidine derivatives |
ATE486838T1 (en) | 2004-05-05 | 2010-11-15 | High Point Pharmaceuticals Llc | NEW COMPOUNDS, THEIR PRODUCTION AND USE |
ATE515494T1 (en) | 2004-05-05 | 2011-07-15 | High Point Pharmaceuticals Llc | NEW COMPOUNDS, THEIR PRODUCTION AND USE |
MX2007016374A (en) | 2005-06-30 | 2008-03-05 | Novo Nordisk As | Phenoxy acetic acids as ppar delta activators. |
CN103224477A (en) * | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | Phenoxy acetic acids as PPAR delta activators |
JP2009529512A (en) | 2006-03-09 | 2009-08-20 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Novel compounds, methods for their production and use |
FR2898271B1 (en) | 2006-03-09 | 2009-01-16 | Pierre Fabre Medicament Sa | NOVEL USE OF ANTIHISTAMINE AGENTS FOR PREVENTIVE TREATMENT OR METHOD OF INFLAMMATORY SYNDROMES, IN PARTICULAR THOSE TRIGGED BY TOGA VIRUSES. |
WO2007141295A1 (en) | 2006-06-08 | 2007-12-13 | High Point Pharmaceuticals, Llc | Process for preparing phenoxy acetic acid derivatives |
EP3043789B1 (en) * | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
-
2006
- 2006-12-21 CN CN2013100979972A patent/CN103224477A/en active Pending
- 2006-12-21 BR BRPI0620468-6A patent/BRPI0620468A2/en not_active IP Right Cessation
- 2006-12-21 EP EP06830789A patent/EP1979311B1/en active Active
- 2006-12-21 WO PCT/EP2006/070096 patent/WO2007071766A2/en active Application Filing
- 2006-12-21 JP JP2008546470A patent/JP5054028B2/en active Active
- 2006-12-21 NZ NZ568488A patent/NZ568488A/en unknown
- 2006-12-21 EA EA201101084A patent/EA201101084A1/en unknown
- 2006-12-21 ES ES06830789T patent/ES2386734T3/en active Active
- 2006-12-21 US US12/097,564 patent/US7943613B2/en active Active
- 2006-12-21 AU AU2006327003A patent/AU2006327003B2/en active Active
- 2006-12-21 EP EP11176836A patent/EP2386540A1/en not_active Withdrawn
- 2006-12-21 EA EA201101085A patent/EA201101085A1/en unknown
- 2006-12-21 CA CA2631390A patent/CA2631390C/en active Active
- 2006-12-21 EA EA200870103A patent/EA015717B1/en not_active IP Right Cessation
- 2006-12-22 TW TW095148358A patent/TWI389878B/en active
-
2008
- 2008-05-22 IL IL191655A patent/IL191655A/en active IP Right Grant
- 2008-07-04 KR KR1020087016288A patent/KR101265078B1/en active IP Right Grant
-
2011
- 2011-04-04 US US13/079,460 patent/US8362016B2/en active Active
-
2012
- 2012-12-07 US US13/708,163 patent/US8551993B2/en active Active
-
2013
- 2013-09-03 US US14/016,442 patent/US9663481B2/en active Active
-
2017
- 2017-04-18 US US15/490,205 patent/US9855274B2/en active Active
- 2017-11-20 US US15/817,470 patent/US10471066B2/en active Active
-
2019
- 2019-11-08 US US16/679,026 patent/US10947180B2/en active Active
-
2021
- 2021-03-09 US US17/196,873 patent/US11420929B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003011807A1 (en) * | 2001-07-30 | 2003-02-13 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
WO2004037775A1 (en) * | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds useful in treating ppar mediated diseases |
WO2004037776A2 (en) * | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds and their use as prar-modulators |
WO2005105735A1 (en) * | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Phenoxyacetic acid derivatives as ppar agonists |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007071766A3 (en) | Phenoxy acetic acids as ppar delta activators | |
WO2007101864A3 (en) | Compounds that modulate ppar activity, their preparation and use | |
WO2008079787A3 (en) | Glucokinase activators | |
WO2010003475A3 (en) | Novel pyrrolidone derivatives for use as metap-2 inhibitors | |
WO2007104034A3 (en) | Glucokinase activators | |
WO2008116107A3 (en) | Piperazine derivatives as glucokinase activators | |
WO2006058648A3 (en) | Biaryloxymethylarene carboxylic acids | |
WO2007041077A3 (en) | Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | |
MX2008014101A (en) | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments. | |
WO2007061923A3 (en) | Glucokinase activators | |
WO2009046841A8 (en) | Piperidine and piperazine derivatives for treating tumours | |
MX2009005048A (en) | New process for the preparation of 2-imino-thiazolidin-4-one derivatives. | |
WO2007100880A8 (en) | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors | |
WO2007106469A3 (en) | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | |
WO2008079814A3 (en) | Mapk/erk kinase inhibitors | |
WO2007032028A8 (en) | Thiazolinones and oxazolinones and their use as ptp1b inhibitors | |
WO2005030120A3 (en) | Antiangiogenic agents | |
WO2006024389A3 (en) | Biphenyl thiazole carboxamides | |
WO2010071783A8 (en) | Thiazoles as cannabinoid receptor ligands | |
WO2009046842A3 (en) | Thiazol derivatives for treating cancer | |
WO2008115890A3 (en) | Mapk/erk kinase inhibitors | |
WO2011008312A3 (en) | Indole and indoline derivatives and methods of use thereof | |
NO20082096L (en) | Azaindole-2-karboksamidderivativer | |
WO2010028338A3 (en) | Novel compounds as cannabinoid receptor ligands | |
WO2007041112A3 (en) | Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680048573.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 191655 Country of ref document: IL Ref document number: 568488 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501233 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006327003 Country of ref document: AU Ref document number: 2631390 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2006327003 Country of ref document: AU Date of ref document: 20061221 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006327003 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008546470 Country of ref document: JP Ref document number: MX/a/2008/008098 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087016288 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006830789 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08074669 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870103 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12097564 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0620468 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080623 |